Compare GSK plc (GSK) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs T-Mobile Us Inc — how do they compare? GSK plc trades at $52.59 (market cap $101.34B), while T-Mobile Us Inc trades at $192.92 (market cap $203.04B). The key difference: T-Mobile Us Inc is far larger — about 2× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TMUS | |
|---|---|---|
Market Cap | $101.34B | $203.04B |
Sector | Health | Media |
52-Week High | $61.18 | $259.01 |
52-Week Low | $36.20 | $167.65 |
Enterprise Value | $121.95B | $320.74B |
Dividend Yield | 3.49% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
TMUS trades at $193.07, up 3.17% today, with strong analyst consensus (83% Buy) and a $241.27 price target. Recent earnings show mixed results with Q1 2026 beating expectations but Q4 2025 missing. Revenue grew to $88.31B in 2025, with net income of $10.99B and robust cash flow from operations of $27.95B. Technical indicators are bullish, with support at $186 and resistance at $193. Leadership changes and competitive threats from Starlink are key developments.
Outlook remains positive due to solid fundamentals and growth trajectory, but risks include rising debt-to-asset ratio (39.35% in 2025) and satellite internet competition. The stock offers value with a P/E of 19.94 and dividend payouts, though investors should monitor execution against earnings forecasts and industry shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
